Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Heitz

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
American Journal of Physiology. Renal Physiology|July 16, 2010
Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathyM Sedeek, G Callera, A Montezano, et al.
European Journal of Biochemistry|July 1, 1983
Brain proteolipids. Isolation, purification and effect on ionic permeability of membranesG Helynck, B Luu, J L Nussbaum, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2012
Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre studyJ Barinoff, R Hils, A Bender, et al.
Science Advances|March 21, 2025
Distortion-free sampling of ultrabroadband terahertz electric fields by interfacial spin accumulationAlexander L Chekhov, Yannic Behovits, Julius J F Heitz, et al.
Archives of Gynecology and Obstetrics|September 20, 2022
Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT databaseM Bossart, H Plett, B Krämer, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysisS I Labidi-Galy, M Rodrigues, J L Sandoval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialE Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
American Journal of Physiology. Renal Physiology|July 16, 2010
Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathyM Sedeek, G Callera, A Montezano, et al.
European Journal of Biochemistry|July 1, 1983
Brain proteolipids. Isolation, purification and effect on ionic permeability of membranesG Helynck, B Luu, J L Nussbaum, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2012
Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre studyJ Barinoff, R Hils, A Bender, et al.
Science Advances|March 21, 2025
Distortion-free sampling of ultrabroadband terahertz electric fields by interfacial spin accumulationAlexander L Chekhov, Yannic Behovits, Julius J F Heitz, et al.
Archives of Gynecology and Obstetrics|September 20, 2022
Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT databaseM Bossart, H Plett, B Krämer, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysisS I Labidi-Galy, M Rodrigues, J L Sandoval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialE Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Pageof 18